Frontiers in Cellular and Infection Microbiology (Jan 2022)

Vaccine Protection of Mice With Primary Immunodeficiencies Against Disseminated Coccidioidomycosis

  • Daniel A. Powell,
  • Daniel A. Powell,
  • Amy P. Hsu,
  • Christine D. Butkiewicz,
  • Hien T. Trinh,
  • Jeffrey A. Frelinger,
  • Steven M. Holland,
  • John N. Galgiani,
  • John N. Galgiani,
  • Lisa F. Shubitz

DOI
https://doi.org/10.3389/fcimb.2021.790488
Journal volume & issue
Vol. 11

Abstract

Read online

Disseminated coccidioidomycosis (DCM), often a severe and refractory disease leading to poor outcomes, is a risk for people with certain primary immunodeficiencies (PID). Several DCM-associated PID (STAT4, STAT3, IFNγ, and Dectin-1) are modeled in mice. To determine if vaccination could provide these mice protection, mice with mutations in Stat4, Stat3, Ifngr1, Clec7a (Dectin-1), and Rag-1 (T- and B-cell deficient) knockout (KO) mice were vaccinated with the live, avirulent, Δcps1 vaccine strain and subsequently challenged intranasally with pathogenic Coccidioides posadasii Silveira strain. Two weeks post-infection, vaccinated mice of all strains except Rag-1 KO had significantly reduced lung and spleen fungal burdens (p<0.05) compared to unvaccinated control mice. Splenic dissemination was prevented in most vaccinated immunodeficient mice while all unvaccinated B6 mice and the Rag-1 KO mice displayed disseminated disease. The mitigation of DCM by Δcps1 vaccination in these mice suggests that it could also benefit humans with immunogenetic risks of severe disease.

Keywords